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Blood vessels arose during evolution carrying oxygen and nutrients to distant organs via complex networks of blood vessels
penetrating organs and tissues. Mammalian cells require oxygen and nutrients for survival, of which oxygen has a diﬀusion limit
of 100 to 200μm between cell and blood vessel. For growth beyond this margin, cells must recruit new blood vessels, ﬁrst by
vasculogenesis, where embryonic vessels form from endothelial precursors, then angiogenesis which is the sprouting of interstitial
tissue columns into the lumen of preexisting blood vessels. Angiogenesis occurs in many inﬂammatory diseases and in many
malignant disease states, including over 90% of solid tumours. Malignant melanoma (MM) is the most lethal skin cancer, highly
angiogenic, highly metastatic, and refractory to all treatments. Raised serum levels of vascular endothelial growth factor (VEGF)
strongly correlate MM disease progression and poor prognosis. Melanoma cells secrete several proangiogenic cytokines including
VEGF-A, ﬁbroblast growth factor (FGF-2), platelet growth factor (PGF-1), interleukin-8 (IL-8), and transforming growth factor
(TGF-1) that modulate the angiogenic switch, changing expression levels during tumour transition from radial to invasive vertical
and then metastatic growth. We highlight modern and historical lines of research and development that are driving this exciting
area of research currently.
1. Angiogenesis
Angiogenesis was ﬁrst associated with malignancy 100 years
ago [1] being new vessel growth from a pre-existing blood
supply. It is physiologically tightly regulated during wound
healing, embryogenesis, and female reproduction. It also
occurs in several pathological conditions including malig-
nant melanoma. In 1919, Krogh described a tissue cylinder
surrounding an axial blood vessel allowing oxygen and
glucose diﬀusion for metabolism [2]. In 1945, vascularised
tumour cell transplants used in vivo murine models survived
to promote tumour survival and growth [3]. A diﬀusible
“angiogenic” substance was later proposed in 1968 using
a hamster cheek pouch model demonstrating choriocarci-
noma vasoproliferation [4]. In 1971, Folkman postulated
that tumour growth and metastasis driven by angiogenesis
might be blocked by inhibiting angiogenesis (6). Later
it was recognised, ischaemic stress occurs as the tumour
growth exceeds the distances of Krogh’s cylinder, resulting in
ischaemic necrosis, or ischaemic/hypoxic induced activation
of angiogenesis [5]w i t hd i ﬀusion limits of oxygen for cell
survival measured at 100–200 microns [6]. Beyond this mar-
gin, angiogenesis facilitates cell growth and survival, demon-
strated experimentally with cultured tumor cells in avascular
rabbit cornea attracting new capillaries and vascularizing the
expanding tumor [7]. In 1976, Gullino showed precancerous
cells acquiring angiogenic capacity in a sequence leading to
cancer [8], leading to a concept of “angiogenic switch” [9].
This is postulated to be crucial to angiogenesis with the
switch “oﬀ” when pro-angiogenic molecules are balanced
by anti-angiogenic molecules, and “on” when this balance
is reversed [10, 11]. “Switch” triggers include low pO2,
low pH [12] or hyper/hypoglycaemia or hyperthermia
[13], mechanical stress, immune/inﬂammatory response,
and genetic mutations [14, 15].2 ISRN Oncology
2.VascularEndothelialGrowthFactor(VEGF)
Central to angiogenesis is VEGF, ﬁrst isolated in 1989
[16]. VEGF promotes endothelial cell proliferation, survival,
migration, vasodilatation, and vasculogenesis by recruiting
bone marrow-derived haematopoetic progenitor cells [17,
18]. VEGF is a heparin-binding family of glycoproteins
including VEGF-A, VEGF-B, VEGF-C, and VEGF-D. VEGF-
A occurs in at least four isoforms of 121, 165, 189, and
201 amino acids length, because of alternative gene splicing.
VEGF-A commonly referred to as VEGF is overexpressed
in almost all solid tumours and correlates with vascularity,
grade, and prognosis [19]. It is also expressed by dendritic
and macrophage immune cells inﬁltrating into tumour
stroma [20]. VEGF ligands bind with variable aﬃnity to
tyrosine kinase receptors expressed on blood endothelial cell
surfaces with vascular endothelial growth factor receptors
(VEGFR) VEGFR-1 and VEGFR-2 involved in angiogenesis
by their binding of VEGF-A isoforms. VEGFR-3 is expressed
on lymphatic endothelial cells and is involved in lymphan-
giogenesis, binding VEGF-C and VEGF-D.
3. The Role of VEGFinMelanoma Angiogenesis
Neovascularisation’s importance in human cutaneous
melanomas was demonstrated to indicate angiogenic
activity [21] and VEGF’s role in melanoma angiogenesis
was ﬁrst demonstrated with the successful transplantation
of human melanoma fragments into a hamster cheek
pouch [22]. Tumor blood ﬂow in melanomas thicker than
0.9mm was detected using Doppler ultrasound [23], and
endogenous VEGF expression and secretion in melanoma
tumour cells were later established [24]. Murine studies
have examined several aspects of VEGF expression and its
role in tumour growth. Transfection and overexpression of
VEGF isoforms in cell lines normally producing baseline
VEGF levels have been an invaluable tool for identifying
diﬀerences in tumorigenicity between isoforms. VEGF121
and VEGF165 promote aggressive tumour growth in mouse
xenografts, contrasting VEGF189 (high heparin aﬃnity/lower
bioavailability) where overexpression demonstrates poor
tumour growth [25].
In vivo murine studies have also shown that aggressive
melanoma cell lines express higher levels of VEGF compared
to nonaggressive cell lines [26]. Nonaggressive cell lines such
as Mel-2 transfected to overexpress VEGF, demonstrated
conversion to an aggressive phenotype producing large
vascularised nonnecrotic tumours in mouse models. These
eﬀects could be reversed with antisense VEGF transfection
resulting in small poorly vascular tumours [27]. These
ﬁndings demonstrate VEGF’s role in aggressive tumour
behaviour.
VEGF-A isoform behaviour may vary with environment.
Nonmetastatic skin melanoma (SKMEL) cells transfected
to overexpress murine VEGF164, an equivalent to human
VEGF165, were subcutaneously implanted into mice, and
demonstrated neovascularisation [27]. Brain metastatic cells
from the human melanoma cell line Mel57 were transfected
to overexpress VEGF165, and coopted pre-existing intra- and
peritumoural vessels without inducing neovascularisation
[28]. Are these clues to MM resistance to treatments, with
tumour behaviour varying according to environment?
Surprisingly VEGF is diﬃcult to detect in skin [29]
and is localised in dermal endothelium but not epithelial
keratinocytes [30] or benign naevi. Dysplastic melanocytes
produce FGF-2 and VEGF. MM by comparison to normal
melanocytes, greatly overexpresses bFGF thereby stimulating
endothelial cell growth and further production of VEGF
[31]. Signiﬁcantly an increase in the secretion and stromal
deposition of VEGF is demonstrable during the switch from
r a d i a lt ov e r t i c a lg r o w t ho fM M[ 32] evidencing a role for
VEGF in the “switch” mechanism. Clinical investigations
with VEGF give conﬂicting conclusions.
Immunohistochemical studies demonstrated upregula-
tion of VEGF165 and VEGF121 and increased microvascular
density in primary melanomas, strongly correlating disease
progression[30,32,33].Converselyasimilaranalysisshowed
only tumour thickness as an independent variable associated
with disease-free survival (Breslow classiﬁcation) and overall
survival—predicted by depth of tumor inﬁltration (Clark
classiﬁcation). Another study found increased vascularity
actually correlated with survival [34].
Bridging this gap in understanding may be the discovery
ofanti-angiogenicVEGFisoformswhichuntilrecentlycould
not be isolated from their pro-angiogenic sister isoforms.
These diﬀer from pro-angiogenic isoforms due to gene
splicing in the 8th exon of the VEGF gene, resulting in same
length ﬁnal protein product, but with a diﬀerent terminal
base sequence encoded in the 8th exon due to splicing
at a novel distal splicing site, conferring anti-angiogenic
properties, denoted VEGFxxxb[ 35].
In vitro and in vivo evidence show VEGFxxxb isoforms
competitively bind VEGFR-2 with equal aﬃnity to pro-
angiogenicisoforms,preventingphosphorylationanddown-
stream intracellular signaling of angiogenic processes [36].
In vivo experiments with VEGF165b transfected melanoma
cellsinnudemicedemonstratedreducedtumourgrowthand
vessel density [37]. Studies with melanoma samples demon-
strated VEGFxxxb to be constitutively expressed in normal
surrounding epidermis, but reduced in primary melanoma
samples (both horizontal and vertical growth phases)
which developed metastasis irrespective of primary tumour
thickness. Total VEGF expression, however, demonstrated
staining in metastatic and Nonmetastatic melanomas and
normal epidermis. Diminished VEGFxxxb expression may
predictmetastaticspreadinpatientswithprimarymelanoma
being crucial in pushing the angiogenic switch, due to
imbalanced VEGF gene splicing to pro-angiogenic isoforms
[38].
Overall, these experimental endeavors have translated
into modest clinical gains, the beneﬁts of which are still
being evaluated and developed. VEGF serum levels do
show prognostic utility, conﬁrming clinically angiogenesis’
importance in MM [39] and a role is being developed for
therapy response monitoring in clinical trials.ISRN Oncology 3
4. Angiopoietins and the TIE Receptor Axis
Angiopoietins bind the receptor tyrosine kinase (RTK)
family of Tie-1 and Tie-2 receptors and are required for
embryonic and adult angiogenesis, interacting with VEGF in
the regulation of angiogenesis and tumour growth through
RTK receptor activation [40].ExperimentallyAng-1agonism
of Tie-2 promotes vascular maturation through pericyte
mediation maintaining endothelial cell (EC) quiescence,
cell survival in pericytes treated in vivo with TNF-α
(whilst pericytes treated with Ang-2 undergo apoptosis),
and pericyte migration [41]. In human umbilical vascular
endothelial cells (HUVECs), VEGF induces Tie-2 and may
therefore promote angiogenesis by inhibition of EC vascular
stabilization [42]. Raised serum levels of Ang-2 are also
associated with advanced disease in melanoma oﬀering a
potential biomarker for disease monitoring.
5.Interleukin-8(IL-8)
IL-8 chemokines are synthesized by macrophages and
endothelial cells primarily inducting chemotaxis in target
cells. Benign melanocytic lesions and normal epidermis
express minimal levels; however, in MM patients IL-8
serum levels are signiﬁcantly higher and correlate with
advanced disease stage and overall patient survival [43]. IL-8
expression in melanoma cells is upregulated in response to
TGF-1, and is pro-angiogenic in mouse xenograft models.
Tumour production of IL-8 not only drives melanoma cell
growth but also promotes tumour cell migration, whilst
endothelial IL-8 induces endothelial cell migration [44].
6.Platelet-Derived Growth Factor (PDGF) and
PDGFRβ Axis
Pericyte and EC crosstalk is inﬂuenced by platelet derived
growth factor (PDGF) which has 5 isoforms, and its TK
receptor platelet derived growth factor receptor (PDGFR)
PDGFRβ. Activation by PDGF leads to receptor dimeri-
sation, autophosphorylation, and signaling transduction
through the PI3K pathway important in EC migration
[45]. During angiogenesis this axis promotes recruitment
of pericytes to the unstable neoangiogenic vasculature.
Pericytes are relatively undiﬀerentiated cells normally lining
the outer surface of endothelial cells contributing to sta-
bility and angiogenesis by producing VEGF. Overexpress-
ing PDGF-BB or PDGF-DD isoforms in a Nonmetastatic
B12 mouse melanoma cell line demonstrated paracrine
eﬀects on tumour growth with pericyte recruitment and
coverage of tumour vessel. The observed reduction in
apoptosis and increased tumour growth is suggested to
be due to increased pericyte expression of VEGF [46].
Endothelial progenitor cells (EPCs) subjected to hypoxic
conditioning demonstrate higher levels of PDGF-BB iso-
form compared to cells in normoxic conditions exert-
ing positive eﬀects on HUVEC cells including increased
proliferation and migration, not observed in HUVECs
exposed to recombinant PDGF-BB alone [47]. These mod-
els examining the eﬀects of hypoxic conditioning on
PDGF overexpression on endothelial cell behaviour sug-
gest an important role for the PDGF/PDGFR signaling
axis in future therapeutic approaches and an important
pathway through which hypoxia stimulates angiogenic
behaviour.
7. Placental GrowthFactor(PGF)
PGF isoforms result from gene splicing and exhibit vari-
able heparin-binding. PGF-1 and -2, are expressed by
melanoma cells binding neuropilin receptors NP-1 and -2
expressed on ECs. NPs are VEGF coreceptors involved in
axon guidance and cell survival and migration [48]. PGF
may also inﬂuence MM development by binding VEGFR-
1 receptors on haematopoietic bone marrow precursors
inducing mobilization and recruitment of inﬂammatory
mediators that upregulate VEGF production around the
tumour,andbybindingVEGFR-1expressingsmoothmuscle
cells and pericytes, thereby aﬀecting blood vessel maturation
and stability [49]. Tumour vessels commonly lack functional
pericytes, which are normally protective against changes in
oxygen or hormonal balance by physically stabilising the
vasculature. The eﬀect of this is to allow hypoxic stimulation
of tumour angiogenesis to go unchecked by the loss of
vasoactive control [50]. PGF also binds VEGF-A forming
heterodimers, directly enhancing melanoma angiogenesis by
VEGFR-2 activation of ECs [51].
8.ExtracellularMatrix (ECM)
The ECM is a complex environment for biochemical and
cellular regulation of gene expression, diﬀerentiation, adhe-
sion, and migration supporting cells and related structures
[52]. EC migration into tumour stroma is essential for
metastasis, and ECs and tumour cells increase metallo-
matrixproteinase(MMP)expressiontofacilitatethisprocess
[53]. The gelatinases MMP-2 and MMP-9 degrade basement
membrane and were the ﬁrst MMP’s linked with angiogene-
sis [54] correlating with invasive and metastatic phenotypes
[55]. MM expresses several MMPs including tissue inhibitor
metalloproteinases (TIMPs) [55]. Raised serum levels of
MT1-MMP and MMP-9 are strongly associated with rapid
disease progression. Raised serum MMP-9 expressed exclu-
sivelyinthehorizontalphaseofmelanomagrowthisstrongly
associated with bone metastases. By contrast, nondysplastic
melanocytes express basal levels of MMP-1 and -9 [56].
Angiogenic mitogens, such as bFGF and VEGF, play a key
role in stimulating capillary endothelial cells to produce
MMPs [57]. Studies also demonstrated MMPs involve-
ment in the angiogenic switch. A tumour model reliably
replicating this switch demonstrated MMP-2si m p o r t a n t
role in developing an angiogenic phenotype [58]. Another
demonstrated MMP-9 inﬂuencing the angiogenic switch
in a pancreatic tumor model [59]. These ﬁndings suggest
MMP/VEGF interaction is critical in initiating angiogenesis
and promoting tumour invasiveness.4 ISRN Oncology
9. Basement Membrane
Basement membrane (BM) is specialised ECM separating
ECs from underlying mesenchyme [60]. BM comprises
collagen type IV, laminin and ﬁbronectin, and heparan sul-
phate proteoglycans (HSPG) [61]. Heparanase secreted from
melanoma cells cleaves heparan sulphate (HS), degrading
this barrier that is normally protective of the basement
membrane’s underlying type IV collagen structure from
proteolysis. This exposes a ligand-integrin binding site for
angiogenesis not found in quiescent vessels [62]. Heparanase
also liberates and activates heparin-binding growth factors
bFGF and VEGF from the ECM, which may act in a
paracrine manner with the tumour [63]. Several melanoma
cell lines degrade ECM through heparanase enzyme degra-
dation [64] and pathological specimens of melanoma tissue
demonstrate increased levels of heparanase mRNA at all
stages of tumour development, with highest expression
found in vertical growth phase samples [65]. Transfection
of the heparanase gene into nonaggressive MM cell lines
demonstrates signiﬁcantly increased enzyme activity and
invasiveness [65]. Heparan sulphate break-down products
also suppress T-lymphocyte immune surveillance in the
environment around the tumour [66]. It is also hypothesized
that invasive melanoma cells may arise by a macrophage-
transformed melanocyte fusion, allowing the tumour to
acquire a “macrophage phenotype,” improving tumour
migratory potential and allowing it to bypass immune
surveillance mechanisms [67–69].
10. Hypoxia-DrivenPathological Angiogenesis
Hypoxia strongly stimulates angiogenesis physiologically or
pathologically, and oxygen tension is a key regulator of
VEGF gene expression in vivo and in vitro [70], with VEGF
mRNA expression induced by low oxygen concentrations in
normal or transformed cultured cells [71]. In melanoma,
hypoxia independently upregulates VEGF [72]a n dt i s s u e
factor (TF) production [73]. TF is a factor VII receptor and
a pathway of hypoxic stimulation for VEGF triggering the
coagulation cascade. In melanoma, this potentiates tumour
cell binding, with cytoplasmic tail tumour cells required for
VEGF synthesis [74]. The second pathway for hypoxic stim-
ulation is through hypoxia inducible factor (HIF) α “master
switch” for transcriptional regulation of cellular responses to
hypoxia, controlling diverse target genes including glycolytic
metabolism, erythropoiesis, and vascular remodeling. HIF is
a 28-base sequence found in the 5 promoter of the VEGF
gene, and mediates hypoxia-induced transcription of VEGF
[75]. It is regulated at protein level by the Von Hippel-
Lindau protein (VHLP) which controls HIF degradation in
normoxic conditions [76]. VHL disease unsurprisingly is
strongly associated with angiogenic neoplasms [77].
11. Hypoxiaand Melanoma
Humanepidermislacksvasculatureandismarkedlyhypoxic.
The O2 tension (pO2)i nd e r m i sh a sap O 2 of 10%, whilst in
some skin appendages the pO2 ranges from mildly (5%) to
severely hypoxic (0.5%) [78]. Human skin exhibits extensive
binding of hypoxia-sensitive agents (such as nitroimidazole
EF5) in the basal epidermal compartment with increased
expression levels of the oxygen sensor HIF-1α [79] and it
is this already hypoxic basal epidermis that may provide
a permissive environment for pushing resident dysplastic
melanocytes into a pro-angiogenic state with hypoxia push-
ing the angiogenic switch. Physiologically mild hypoxia of
the skin can promote melanocyte transformation [80, 81]
and correlate with increased expression of HIF-1α,H I F -
2α, and VEGF, found commonly in melanoma samples,
and poor prognosis and survival [82]. Hypoxia directly
stimulates tumour blood vessel formation in response to
HIF induced VEGF production. In MM, this results in
vessels structurally and functionally abnormal with shunts
contributing disordered tumor blood ﬂow [83] exacerbating
hypoxic/acidic regions in the growing tumour [84]. Mis-
matched vascularity and oxygenation further inﬂuences the
balance of angiogenic stimulators and inhibitors in favor of
angiogenesis, aiding malignant/metastatic cell selection [85].
12. Conclusions
Angiogenesis is a hallmark of cancer [10], and VEGF is
ak e yp l a y e r[ 16]. Evidence shows its involvement at key
elements of tumour growth; including tumour hypoxia trig-
gering HIF-induced VEGF production, endogenous tumour
production of VEGF, tumour-endothelium paracrine inter-
action and upregulation of VEGF, liberation of VEGF from
the ECM by tumour heparanase production, or recruitment
of VEGF producing macrophages. Whether these processes
are sequentially linked or not, the common denominator
is VEGF. Anti-angiogenic isoforms are gradually emerging
in the research sphere [35] and may provide invaluable
prognostic information [38], and in the future therapeutic
possibilities. We hypothesise that melanoma cells express at
low levels (unpublished data) VEGF receptors in pro- or
anti-angiogenic isoforms, the balance of which is governed
by splicing, in turn inﬂuenced by factors that modulate
the angiogenic switch, and upregulating VEGF receptor
expression as a tumour survival response. This process of
“survival” growth may facilitate further tumour growth by
causing localised intratumoral hypoxia which is a powerful
stimulus to HIF-1α production and therefore more neovas-
cularisation. Upregulating VEGF receptors at the tumour
surface or tumour-endothelial cell interface may occur as a
prelude to tumour ECM interaction with MMPs. Whether
the angiogenic switch is pushed by a preponderance of
proangiogenic VEGF or by VEGF splicing from anti- to
pro-angiogenic forms is unclear; however, this critical event
appears directly related to the tumour change from radial
to invasive growth and may represent the culmination of
a sequence of processes. This relationship has not yet been
linked in a uniﬁed model that gradually upregulates pro-
angiogenic VEGF to this critical level.
Melanoma cells also produce heparanase disrupting
the basement membrane facilitating tumour cell invasion.
Macrophages possibly add fuel to the ﬁre bringing greaterISRN Oncology 5
quantities of VEGF to the tumour site setting up new VEGF
gradientsfavoringtumourgrowth,whichinturnmayupreg-
ulate MMPs and therefore metastatic behaviour. Heparin-
treated tumour cells demonstrate reduced cell adhesion and
migration [86], and given that heparin-binding sites are
splicedduringsynthesisofVEGFisoforms,investigatinghow
heparin may aﬀect the eﬃcacy of VEGF isoforms on tumour
growth in vitro would be intriguing.
A tumour thus enriched by numerous sources of pro-
angiogenic growth factor, and at the same time appearing
to enjoy immune privilege, is able to liberate VEGF from
the ECM which acts as a standing reservoir of VEGF and
facilitate invasion and metastasis.
Future research might focus on tumour VEGF isoform
characterization, distribution and site-speciﬁc variability,
and the inﬂuence on disease progression. Examining the
possible role of splice variants in hypoxic states such
as pregnancy in melanoma (indeed murine models show
increased lymphangiogenesis and metastasis in pregnancy
[87]) could yield valuable insights.
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